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Abstract
Background: Epilepsy is genetically complex but common brain disorder of the world affecting millions of people
with almost of all age groups. Novel Copy number variations (CNVs) are considered as important reason for the
numerous neurodevelopmental disorders along with intellectual disability and epilepsy. DNA array based studies
contribute to explain a more severe clinical presentation of the disease but interoperation of many detected CNVs
are still challenging.
Results: In order to study novel CNVs with epilepsy related genes in Saudi family with six affected and two normal
individuals with several forms of epileptic seizures, intellectual disability (ID), and minor dysmorphism, we
performed the high density whole genome Agilent sure print G3 Hmn CGH 2x 400 K array-CGH chips analysis. Our
results showed de novo deletions, duplications and deletion plus duplication on differential chromosomal regions in
the affected individuals that were not shown in the normal fathe and normal kids by using Agilent CytoGenomics
3.0.6.6 softwear. Copy number gain were observed in the chromosome 1, 16 and 22 with LCE3C, HPR, GSTT2,
GSTTP2, DDT and DDTL genes respectively whereas the deletions observed in the chromosomal regions 8p23-p21
(4303127–4337759) and the potential gene in this region is CSMD1 (OMIM: 612279). Moreover, the array CGH results
deletions and duplication were also validated by using primer design of deleted regions utilizing the flanked SNPs
using simple PCR and also by using quantitative real time PCR.
Conclusions: We found some of the de novo deletions and duplication in our study in Saudi family with
intellectual disability and epilepsy. Our results suggest that array-CGH should be used as a first line of genetic test
for epilepsy except there is a strong indication for a monogenic syndrome. The advanced high through put
array-CGH technique used in this study aim to collect the data base and to identify new mechanisms describing
epileptic disorder, may help to improve the clinical management of individual cases in decreasing the burden of
epilepsy in Saudi Arabia.
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Background
Epilepsy in human is among one of the utmost common
brain disorder with 1 % occurrence and characterized by
regular and unprovoked seizures due to irregular electric
activity in central nervous system (CNS) [1]. Until now
there are more than 50 different epileptic syndromes
with wide range of clinical features have been identified.
Epilepsy can be divided as idiopathic or symptomatic
epilepsies. Infections, metabolic disorders, brain tumors,
head trauma, or stroke are the main reasons of symp-
tomatic epilepsy whereas genetic contributions are the
main cause of the idiopathic seizure [2]. In human
genetics structural changes are largely unexplored area
that may be the common factor of epileptic disease [3].
These changes include deletions, duplications insertions,
inversions, and translocations of DNA sequences, and
includes copy number differences also known as CNVs
[4, 5]. Recently the development of advanced technolo-
gies for genome wide studied such as array-CGH helped
to detect minute amplifications and deletion in the
chromosomal region [6, 7]. CNVs are the most import-
ant component of genetic variation and act as important
players in the genetic etiology of various neurodevelop-
mental disorders. CNVs are developing as an important
genetic contribution to identify a wide range of epilep-
sies, such as common new discoveries in epilepsies from
genetic generalized epilepsies to the individually rare
particular epileptic of encephalopathies [8]. The role of
CNVs highlighted in the etiology of number of disorders
such as intellectual disability (ID) [9] autism [10, 11],
schizophrenia [12, 13] and epilepsy [14, 15]. Now a days
various free databases for pathogenic and normal
genome variations are available on internet and these
are exceptionally valuable tools for interpretation of
CNVs identified in normal and patients such as Database
of Chromosomal Imbalance and Phenotype in Humans
Using Ensembl Resources: DECIPHER and Database of
Genomic Variants: DGV;).
In this study, we observed de novo CNVs gain and
deletion in a large family with affected mother and five
affected kids having intellectual disability, epilepsy and
some member with mild intellectual disability nd we
hypothesized that genes found within those CNVs
would be novel candidate for epilepsy. We are reporting
de novo CNVs and the genes cluster in that deleted or
amplified region only in the affected members of the
family that might be helpful to understand the genetic
etiology of epilepsy.
Results and discussion
Our Array-CGH results showed deletion as well as
duplication in different genomic regions of effected
member of the epileptic patients of the family (Fig. 1). In
this data, we reported the results of the family with five
affected member satisfying the cut off value of gain and
deletions (−1.0 for deletion and 0.8 for duplication).
Deletion was observed in chromosome 8 with cytoband
8p23-p21 CSMD1 gene and copy number gain were
observed in the chromosome 1, 16 and 22 with LCE3C,
HPR, GSTT2 and GSTTP2 genes respectively. These
observed CNV findings were confirmed by using the
qPCR analysis.
Microarray data showed deleted CNVs
Our results of whole genome 2x 400 K oligonucleotide
microarray analysis showed deletions 8p23.1 start
4,310,831 end 4,329,349 in four affected member of the
family and important gene in this region name as CUB
and sushi multiple domains 1 (CSMD1) (Fig. 2). This
gene is large size (1 Mb) similar to CSMD3 which maps
in the region of 8q23 and already been associated with
mental retardation, autism and to epilepsy [16–19].
The gene CSMD1 is a unique multiple domain
complement-regulatory protein, which is highly
expressed in the epithelial tissues and CNS and play a
role as important regulator of complement initiation and
inflammation in the developing.
CNS and also play role in the context of growth cone
function [20]. The deleted region in our patient is at the
start of CSMD1 and all the affected member having the
language delay, learning difficulties and epilepsy as
shown to be totally deleted (haploinsufficiency) and
interrupted by the breakpoint patients with autism and
‘severe language delay’ and learning difficulties reported
by [21, 22].
These deletion were confirmed by qPCR which have
shown a significant deletions in the gene copy num-
ber in affected mother and three kids he same family
(Fig. 3). We screened ethnically matched healthy con-
trol chromosomes (n = 50) to ensure that the copy
number deletions did not represent a normal popula-
tion, and verified that it was not present outside the
family.
Microarray data showed CNVs copy number gain
Our results of whole genome 2x 400 K oligonucleotide
showed CNVs gain at chromosome 1 in the four affected
members of the family starts from 150,819,879–
150,819,938 cytoband 1q21.3 and the potential gene in
this region is LCE3C (Fig. 4). Previously LCE deletion
was related with psoriasis [23, 24] but no region have
been associated with epilepsy or autism. Recently, late
comified envelope (LCE) genes especially the cluster 3
(LCE3) genes mutation influence developing psoriasis
and psoriatic arthritis [25]. We found this CNV in our
four affected individuals and this amplification was not
seen in the normal individuals of the family. Further, in
future analysis will be necessary to determine if this
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CNV especially the LCE3C gene is an epilepsy and aut-
ism risk variant in Saudi population (Fig. 4b).
We also found gain at chromosome 16 that starts from
70,647,078–70,669,681 cytoband 16q22.2 in our all five
affected members of the family and the potential gene in
this region is HPR gene code haptoglobin protein in
plasma acts as a scavenger for free heme, and
haptoglobin-related protein (coded by the HPR gene)
(Fig. 4a). In African-Americans HPR gene copy number
variation has been reported, where extra copies of the
HPR gene have been produced by non-allelic homolo-
gous recombination [26].
Fig. 2 Array-CGH profiles analysis using Agilent CytoGenomic Analytics software (V.3.0.6.6) showing the deletion. Zero value indicates equal
fluorescence intensity ratio between the sample and reference. Copy number losses shifted the ratio toward left (red), whereas copy number
gains towards the right side (blue). CNV deletions observed in the chromosomal regions 8p23-p21 in four affected members of the family starts
from 4,303,127 end 4,337,759 and the potential gene in this region is CSMD1 (OMIM: 612279)
Fig. 1 A consanguineous family pedigree from Saudi Arabia with intellectual disability and epilepsy. The available samples for microarray and
validation study are marked with asterisks
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Previously, duplication of HPR gene showed a
slight, non-significant under transmission to human
African trypanosomiasis-affected children from normal
parents in the Democratic Republic of Congo [27].
There is no study available that link this gene to
epilepsy, intellectual disability and autism so we
suggest further investigation of this duplication the
Saudi population.
Our micro array data showed another copy number
gain at chromosome 22 starts 22,686,690–22,735,300
cytoband 22q11.23 and the gene cluster in this region is
GSTT1, GSTTP2, GSTT2B, GSTT2, DDT, and DDTL.
Additional analysis through qPCR confirmed the dupli-
cations that has shown a significant fold increase in the
GSTT1, GSTTP2, GSTT2B GSTT2 gene copy number
compared to the controls (Fig. 4c). Glutathione S-trans-
ferase theta 1 (GSTT1) are a member of superfamily of
enzymes that play role in both protection from oxidative
damage and detoxification [28]. In liver they play an
important role in metabolizing antiepileptic drugs
(AEDs) [29, 30]. Many AEDs produce active metabo-
lites, including epoxides, which might have result on
suppression of epileptic spike, but inappropriately,
also in systemic toxicity through covalent binding to
lipids and proteins [29]. Glutathione S-transferase
(GSTs) help in catalyzing the conjugation of these
metabolites to glutathione, particularly in the elimin-
ation of epoxide metabolites that are produced during
AEDs metabolism. GSTs not only help in decreasing
their toxicity and helping their excretion from the
body, it is expected that GSTs may also affect the re-
sponse to anticonvulsant therapy [29, 31].
Previously it has been reported that replication of the
22q11.23 region associated with schizophrenia [32–37]
further support the hypothesis that effect of copy
number of GSTT2 may be that the regional structural
variation would impact the risk of schizophrenia by
altering controlling elements for other genes close to
the region. Actually, this area shows a high density of
segmental duplications and CNV that may impact the
expression of surrounding genes in that area [38, 39]
Furthermore, the discovery of disease linked with
GST genes elsewhere in the genome, suggests a direct
effect of GSTT2 gene changes leading to the risk of
schizophrenia [40]. Our microarray data showing the
similar information that this region is involved in
epilepsy as previously explained [40] duplication at
chromosome 22 with gene cluster GSTT1, GSTTP2,
GSTT2B, GSTT2, DDT and DDTL showing the similar
phenotypes in our clinical information in the affected
member of the family with epilepsy, intellectual dis-
ability and also leading to schizophrenia may be the
candidate genes for this complex syndrome (Fig. 4c).
These duplications were confirmed by qPCR which
have shown a significant increase in the gene copy
number in only four patients of the same family
(Fig. 5a, b, c).
Conclusion
In the development of neurological disorders CNVs
play important role and may contribute in the genetic
etiology of epilepsy. Our results showed novel CNVs/
genes for the first time in Saudi family with six af-
fected member with intellectual disability and epi-
lepsy. Our results enhanced the knowledge of the
copy number variants underling in epilepsy in Saudi
population. This could provide a basis for the under-
standing of the chromosomal region that will be
critical in the genome may be involved in the devel-
opment of epilepsy, intellectual disability and further
linked with schizophrenia. Further detailed studies
and complete clinical information of the patients and
Fig. 3 Confirmation of deleted and gained CNVs region by using qPCR analysis. The results have shown CSMD1gene copy number deletions in
the mother and three affected member of the family showed significant fold change as compared to the control
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Fig. 4 a Array-CGH profiles analysis using Agilent CytoGenomic Analytics software (V.3.0.6.6). Zero value indicates equal fluorescence intensity
ratio between the sample and reference. Copy number losses shifted the ratio toward left (red) whereas copy number gains towards the right
side (blue). CNVs gain at chromosome 1 starts from 150,819,879–150,819,938 cytoband 1q21.3 in the four affected members of the family and the
potential gene in this region is LCE3C. b Our results showed the gain at chromosome 16 that starts from 70,647,078–70,669,681 cytoband 16q22.2
in our all four affected members of the family and the potential gene in this region is HPR gene. c Our results showed gain at chromosome 22
starts 22,686,690–22,735,300 cytoband 22q11.23 and the potential gene cluster in this region are GSTT1, GSTTP2, GSTT2B, GSTT2, DDT, and DDTL in
all affected members of the family
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identification of possible causative CNVs and genes in
the CNV regions using array technology will be ob-
ligatory to identify novel syndromes that will help to
improve the diagnosis of epilepsy.
Methods
Epileptic family
A large consanguineous pedigree of epileptic’s family
with six affected (two female and all four male affected)
and two normal individuals along with normal father
and affected mother was enrolled for this study as
shown in Fig. 1. Written informed consent was obtained
from the study participants themselves or from the par-
ents of children. The study was approved by the Center
of Excellence in Genomic Medicine and Research King
Abdulaziz University, following Helsinki Declaration of
research and ethics standards. The family was primarily
diagnosed as epileptic family and all the children and
mother having epilepsy along with different clinical
features such as mother was diagnosed as juvenile
myoclonic epilepsy as the seizure started at the age of
16 years whereas the proband IV-1 having epilepsy with
myoclonic seizures, muscle twitching along with uncon-
trolled jerking of the body sickle cell anemia and
osteoporosis, proband lV-4 having epilepsy with
myoclonic seizures and mild intellectual disability, while
proband IV-6 having seizure with muscle twitching and
uncontrolled body jerk.with speaking problems and IV-7
and IV-8VIII having seizure with myoclonic jerks with
intellectual disability. In all the affected member of the
family the seizure was started at different age group such
as in mother seizure started when she was 16 years old
and still suffering with this disease.
DNA preparation
All the family member visited the clinic and blood
samples from affected and normal individuals has been
taken at King Abdulaziz University Hospital with their
informed consent after the approval of the ethical
committee. Genomic DNA was obtained from the blood
through the QIAamp DNA blood mini kit followed by
the protocol from the manufacturer.
Array-CGH analysis
Genomic DNA fragmentation
The array-CGH analysis was performed by Agilent sure
print G3 Hmn CGH 2x 400 K arrays (Agilent Technolo-
gies, USA) followed the protocol as provided by the
manufacturer. Briefly, 500 ng of patient’s DNA along
reference DNA of the similar sex (Promega, USA). RsaI
and AluI enzymes used to digest the DNA and incubated
for 2 h at 37 °C. The reference DNA was heat fragmen-
ted for 10 min at 95 °C.
Fig. 5 a, b, c Confirmation of CNVs by qPCR have shown a significant fold increase in a LCE3C, b HPR, and c GSTT2 gene copy number in the
patients of the family member as compared to the healthy individuals
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Fluorescent labeling, purification and hybridization
The digested DNA from affected and normal family
member were labeled via random priming through
Agilent labeling kit (Agilent Technologies, USA) follow-
ing the manufacturer guidelines. Patient’s and reference
DNA was labelled with Cy5-dUTPand Cy3-dUTP
respectively. For the purification of the labelled samples,
the Microcon YM-30 filter units were used (Millipore,
USA). The DNAs from patient and reference were
mixed with Cot-1 DNA (Invitrogen, USA) used as
blocking agent along with hybridization buffer as per
manufacturer instructions. Hybridization was done at
65 °C for 40 h, after the denaturation at 95 °C.
Microarray chip washing and scanning
After the hybridization, microarrays and gaskets were dis-
assembled in wash buffer 1 (Agilent Technologies). The
slides were shifted to the wash buffer 2 after 05–30 min,
(Agilent Technologies) and agitated at 37 °C for 01 min
followed by the washing of slides with anhydrous aceto-
nitrile. Scanning and image analysis were performed as
per oligonucleotide array-CGH protocol (Agilent, version
4.0). Microarrays were scanned through Agilent Scanner
(G2505C) and the data was extracted through Agilent’s
Feature Extraction software (V.1.5.1.0).
Data analysis
Agilent CytoGenomic Analytics software (V.3.0.6.6) was
used to visualize, detect and analyze the aberrations
deletion and duplication from microarray profiles using
Tiff images from data.
Real-time PCR
Real-time quantitative PCR (qPCR), used to confirm the
deletions and duplications detected by array-CGH
analysis. Primer were designed for the targeted region
for validation using real time PCR analysis. Primers were
selected for deleted and copy number gain in the gen-
omic region for CUB and sushi multiple domains 1
(CSMD1) gene; LCE3C, HPR, and GSTTP2, genes re-
spectively and an endogenous gene β2-microglobulin
(B2M) and control samples. The reaction was run in a
final volume of 10 μl, comprising of 05 μl SYBR-Green
qPCR master mix (KAPA Biosystems, USA), 10pmol of
each primer and 20 ng genomic DNA. All the deletion
and duplications was conformed in triplicate for each
sample in a 96 well plate which includes control sam-
ples, target genes, reference gene and non-template con-
trol for each gene. Each run was analyzed with
StepOnePlus™ Real-Time PCR Systems (StepOnePlus™
Real-Time PCR, Applied Biosystems, Canada). The Ct is
the threshold cycle at which the fluorescence curve
reaches an arbitrary threshold; ΔCt is the difference be-
tween the Ct of the target gene and that of the reference
gene; ΔΔCt is the ΔCt value of the patients obtained by
dividing the ΔCt value of the patient with ΔCt value of
the control sample. The T-test with significant P-value
<0.05 was performed to find out statistical significance
of the predicted copy number alterations. The sequence
of the primers used in the validation studies are added
in Table 1.
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